Skip to main content

Don’t worry Kevin Nealon, this anticoagulant antidote should be approved soon

Andexanet Alfa Mechanism of Action (MOA) Video
Most of us might recognize Xarelto from the commercial with Kevin Nealon and Arnold Palmer. Unless you or someone you know takes it, you probably don’t know that it causes some patients to bleed uncontrollably after trauma. Xarelto, a blood-thinner, was approved as a safer warfarin alternative for patients at high risk of a stroke months ago, but it still had its dangers. Now a new drug is up for approval.
Xarelto Commercial 2015 Kevin Nealon, Brian Vickers

Earlier this month, Portola Pharmaceuticals posted the application for the drug, andexanet alfa, which quickly reverses the anticoagulant effects of Xarelto and Eliquis. It’s expected to be approved and hit the market in 2016. This anti-coagulant antidote can prevent major bleeding episodes in patients taking those highly advertised medications.

According to Reuters, an emergency physician at Thomas Jefferson University Hospital, Dr. Charles Pollack said, “It may be uncommon, but they’re memorable when they happen … We didn’t have a specific reversal strategy for these drugs and I think that left people feeling a bit insecure.” It’s not hard to imagine such incidents must be terrifying for patients, and apparently for doctors too.

“I have many physicians, particularly surgeons, who hate these drugs,” Dr. Mariell Jessup, cardiologist at the University of Pennsylvania Medical Center explained. “They’re frightened of them because they’ve had to deal with the consequences of somebody coming in with trauma.”

Like warfarin, Xarelto and Eliquis are intended for patients suffering from atrial fibrillation, a type of irregular heartbeat that makes a person much more likely to have a stroke. Xarelto doesn’t place the same restrictions on the patient’s diet and may cause fewer major bleeding incidents compared to warfarin, but still reduces a person’s ability to form blood clots and therefore stop bleeding. Having an antidote like andexanet alfa puts patients and doctors at ease and decreases risk dramatically. Unfortunately, Portola’s first drug is not intended for use with warfarin, aka Coumadin, which still commands 60 percent of the anti-coagulant market.

Editors' Recommendations

Aliya Barnwell
Former Digital Trends Contributor
Aliya Tyus-Barnwell is a writer, cyclist and gamer with an interest in technology. Also a fantasy fan, she's had fiction…
Aptiv’s machine learning-powered radar sees even what you don’t
lyft and aptivs self driving car program has come a long way but not far enough aptiv screen press

Aptiv traveled to CES 2022 to showcase the improvements it has made to its suite of advanced driver assistance systems. It notably leveraged the power of machine learning technology to help its self-driving prototypes detect and classify objects, even those that are out of sight.

Think of a self-driving car as a human being; radars are the eyes and machine learning technology is the brain. Fitting radars to a car's body allows it to scope out the environment it operates in. It can detect that there's a car in front of it, that there's a bike coming the other way, and that there's a traffic light it needs to stop for. These are fairly straightforward tasks that most self-driving prototypes already perform.

Read more
Fortnite is down with players being told they don’t ‘have permission to play’
Statue in Fortnite.

As kids and adults alike enjoy their holiday breaks, one thing they won't be doing, for now, is playing Fortnite. The massively popular battle royale title has gone offline.

While Epic games has previously closed the game's servers to update it, like with its recent Chapter 3 update, the sudden issues preventing players from logging in are not part of the developer's plan.

Read more
Don’t buy the Apple Watch Series 3 anymore — it’s not worth it

After Apple announced the long-awaited Apple Watch Series 7, you may have found your eyes, and especially your wallet, drawn to the idea of the Apple Watch Series 3 dropping its price to a downright affordable $199. While it won't have any of the features of the Series 7, like upgraded specs, improved battery life, a fancy new design, and a plethora of new features, it'll come in at $200 less, compared to the $399 Series 7. This may sound like a deal on its face. But we advise against falling for this ruse.

Here's why:
A design that hasn't aged well
First, put this timeline into perspective. Apple released the Series 3 in September 2017. The design back then didn't put it out of step with other smartwatches on the market. At release, we even praised it in our review as a "joy to use" and the "best smartwatch you can buy." That was true then, but in 2021 the design has started to show its age.

Read more